Efficacy and safety of vitamin K plus sorafenib combination treatment against hepatocellular carcinoma-Open label, randomized, phase 2 study.

被引：0
|
作者：
Haruna, Yoshimichi [1 ]
Inoue, Atsuo [1 ]
机构：
[1] Osaka Gen Med Ctr, Dept Gastroenterol & Hepatol, Osaka, Japan
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1383
引用
收藏
页码：741A / 741A
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of vitamin K with sorafenib combination treatment against hepatocellular carcinoma: Open-label, randomized phase II study.
    Haruna, Yoshimichi
    Inoue, Atsuo
    Kawamoto, Seiichi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study
    Haruna, Yoshimichi
    Yakushijin, Takayuki
    Kawamoto, Seiichi
    CANCER MEDICINE, 2021, 10 (03): : 914 - 922
  • [3] The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.
    Yang, Xin-Rong
    Cheng, Jian-Wen
    Wu, Suiyi
    Hu, Bo
    Qiu, Shuang-Jian
    Sun, Hui-Chuan
    Fan, Jia
    Zhou, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study
    Srimuninnimit, Vichien
    Sriuranpong, Virote
    Suwanvecho, Suthida
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 255 - 260
  • [5] Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    He, Aiwu Ruth
    Lim, Ho Yeong
    Ryoo, Baek-Yeol
    Hung, Chao-Hung
    Sheen, I-Shyan
    Izumi, Namiki
    Austin, TaShara
    Wang, Qiang
    Greenberg, Jonathan
    Shiratori, Shinichi
    Beckman, Robert A.
    Kudo, Masatoshi
    JOURNAL OF HEPATOLOGY, 2015, 63 (04) : 896 - 904
  • [6] Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma
    Sinakos, Emmanouil
    Dedes, Ioannis
    Papalavrentios, Lavrentis
    Drevelegas, Antonios
    Akriviadis, Evangelos
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2010, 45 (04) : 511 - 512
  • [7] Efficacy and safety of a phase II study of sorafenib plus gemcitabine in advanced hepatocellular carcinoma.
    Srimuninnimit, V.
    Sriuranpong, V.
    Suwanvecho, S.
    Soparattanapaisarn, N.
    Ithimakin, S.
    Akewanlop, C.
    Tanasanvimon, S.
    Parinyanitikul, N.
    Kiatikajornthada, N.
    Suwanrusme, H.
    Chaiyarat, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] An investigation of the safety of continued treatment with sorafenib in patients with unresectable hepatocellular carcinoma after the first disease progression: Multicenter, open-label, phase II safety study.
    Akutsu, Noriyuki
    Sasaki, Shigeru
    Takagi, Hideyasu
    Kaneto, Hiroyuki
    Yonezawa, Kazuhiko
    Yawata, Atsushi
    Adachi, Takeya
    Yokoo, Hideki
    Kamiyama, Toshiya
    Hamamoto, Yasuo
    Shinomura, Yasuhisa
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [9] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
    Ali A. Mokdad
    Hao Zhu
    Muhammad S. Beg
    Yull Arriaga
    Jonathan E. Dowell
    Amit G. Singal
    Adam C. Yopp
    Targeted Oncology, 2019, 14 : 541 - 550
  • [10] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
    Mokdad, Ali A.
    Zhu, Hao
    Beg, Muhammad S.
    Arriaga, Yull
    Dowell, Jonathan E.
    Singal, Amit G.
    Yopp, Adam C.
    TARGETED ONCOLOGY, 2019, 14 (05) : 541 - 550
12345